Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Cora N. Sternberg(Cornell University), Roberto Sabbatini(Azienda Ospedaliero-Universitaria di Modena), Sebastiano Buti(University of Parma), Alessandra Raimondi(Fondazione IRCCS Istituto Nazionale dei Tumori), Camillo Porta(University of Pavia), Davide Tassinari(University of Bologna), D. Turci(Azienda Ospedaliera San Camillo-Forlanini), Giacomo Cartenì(Ospedale Antonio Cardarelli), Sabrina Rossetti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giampaolo Tortora(University of Naples Federico II), Francesco Cognetti(Apple (Israel)), Elena Verzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonio Pazzola(Azienda Ospedaliero Universitaria di Sassari), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Francesca Rastelli(Associazione Italiana Di Oncologia Medica), Andrea De Giglio(Azienda USL di Bologna), Stefano Panni(Istituti Ospitalieri di Cremona), Diana Giannarelli(Agostino Gemelli University Polyclinic), Enrico Cortesi(Sapienza University of Rome), Alberto F. Sobrero(Ospedale Policlinico San Martino), Federico Cappuzzo(Ospedale di Livorno), Gianmarco Surico(Ospedale Vito Fazzi)
Cited by 140
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k